Finance

Lists
KNSA:NASDAQ
Kiniksa Pharmaceuticals Internatinl, PLC
US$ ८८.३४
०.००%
(०.००) 1D
US$ ८९.००
+०.७५% (+०.६६)
Pre-market
Closed: नोभेम्बर ५, १६:००:०० GMT-५  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for KNSA...
Mkt. cap
६.९४ अरब
Avg. vol.
८.३१ लाख
Volume
१०६.००
P/E ratio
६७.४३
52-wk high
US$ ९८.४८
52-wk low
US$ ३७.०२
EPS
US$ १.३१
Beta
०.०७
Shares outstanding
४.८८ करोड
No. of employees
३६६
Mkt. cap
६.९४ अरब
Avg. vol.
८.३१ लाख
Volume
१०६.००
P/E ratio
६७.४३
52-wk high
US$ ९८.४८
52-wk low
US$ ३७.०२
EPS
US$ १.३१
Beta
०.०७
Shares outstanding
४.८८ करोड
No. of employees
३६६
News stories
From web sources and news partners
About Kiniksa Pharmaceuticals Internatinl, PLC
CEO-
Employees३६६
Founded२०१५
Headquartersलण्डन, इङ्ल्यान्ड, संयुक्त अधिराज्य
SectorHealth Care
Industry-
Websitekiniksa.com
Analyst ratings
Based on 5 analysts giving stock ratings to KNSA in the past 3 months
Strong buy
Buy
5
Hold
0
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for KNSA in the last 3 months.
Highest
Current US$ ८८.३४
US$ १२२.०० (+३८.१०%)
Average
US$ १०६.२० (+२०.२२%)
Lowest
US$ ९८.०० (+१०.९४%)
Analyst
Recommendation
Action
Price target
Projected
Date
Anupam Rama
J.P. Morgan
Buy
Reiterated
US$ १२२.००
+३८.१%
10/30/2026
Edward Nash
Canaccord Genuity
Buy
Maintained
US$ ९८.००
+१०.९%
10/28/2026
Yanan Zhu
Wells Fargo
Buy
Maintained
US$ ११०.००
+२४.५%
10/28/2026
Paul Choi
Goldman Sachs
Buy
Reiterated
US$ १०१.००
+१४.३%
10/27/2026
Geoff Meacham
Citi
Buy
Maintained
US$ १००.००
+१३.२%
10/15/2026
David Nierengarten
Wedbush
Buy
Reiterated
US$ ९९.००
+१२.१%
07/28/2026
Eva Fortea Verdejo
Wells Fargo
Buy
Reiterated
US$ ८७.००
-१.५%
07/29/2026
Nicholas Lorusso
TD Cowen
Buy
Reiterated
US$ ९५.००
+७.५%
07/28/2026
Roger Song
Jefferies
Buy
Maintained
US$ ७१.००
-१९.६%
04/28/2026
Unknown Analyst
Wells Fargo
Buy
Maintained
US$ ५३.००
-४०%
04/14/2026
Last report
२०२६ अक्टोबर २७
Fiscal period
Q3 2026
US$ ०.५६ / US$ ०.३१
+७९.२०%beat
Revenue / Est. (USD)
२८.६० करोड / २६.०६ करोड
+९.७३%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
२०२५ डिसेम्बर
२०२६ मार्च
२०२६ जुन
२०२६ सेप्टेम्बर
Revenue
२०.२१ करोड
२१.४३ करोड
२४.३६ करोड
२८.६० करोड
Cost of goods sold
९.१० करोड
९.६४ करोड
११.१६ करोड
१३.३६ करोड
Cost of revenue
९.१० करोड
९.६४ करोड
११.१६ करोड
१३.३६ करोड
Research and development expenses
३.४६ करोड
२.७५ करोड
४.०९ करोड
३.२८ करोड
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
५.६८ करोड
६.१२ करोड
६.३९ करोड
६.५४ करोड
Operating expense
९.१४ करोड
८.८६ करोड
१०.४८ करोड
९.८१ करोड
Total operating expenses
१८.२४ करोड
१८.५० करोड
२१.६४ करोड
२३.१७ करोड
Operating income
१.९८ करोड
२.९३ करोड
२.७२ करोड
५.४२ करोड
Other non operating income
३५.०१ लाख
३४.१४ लाख
३९.५१ लाख
-१.६९ लाख
EBT including unusual items
२.३३ करोड
३.२७ करोड
३.११ करोड
५.९१ करोड
EBT excluding unusual items
२.३३ करोड
३.२७ करोड
३.११ करोड
५.९१ करोड
Income tax expense
९०.७० लाख
१.०१ करोड
५७.१३ लाख
१.१७ करोड
Effective tax rate
३८.९८%
३०.८७%
१८.३४%
१९.८३%
Other operating expenses
-
-
-
-
Net income
१.४२ करोड
२.२६ करोड
२.५४ करोड
४.७३ करोड
Net profit margin
७.०२%
१०.५४%
१०.४४%
१६.५६%
Earnings per share
०.१७
०.२७
०.३०
०.५६
Interest and investment income
-
-
-
४९.९० लाख
Interest expense
-
-
-
-
Net interest expenses
-
-
-
४९.९० लाख
Depreciation and amortization charges
-
-
-
-
EBITDA
२.०२ करोड
२.९७ करोड
२.७७ करोड
५.४७ करोड
Gain or loss from assets sale
-५३.०० हजार
-५४.०० हजार
२२.०० हजार
८.०० हजार
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google एपहरू